Deficiencies in interferon-stimulated gene 15 (ISG15), a protein that normally regulates the immune response, causes mild but persistent inflammation. However, its absence also provides an unexpected ...

Celldex Therapeutics Inc. will not advance barzolvolimab (CDX-0159, barzo) in eosinophilic esophagitis (EoE) after taking a ...

Cohesys Inc. conducted the first test of its resorbable Bonetape in humans as part of an investigational trial for craniofacial fractures. The tape could eliminate the use of drills and screws in many ...

Researchers at the Massachusetts Institute of Technology have developed a generative AI model that was able to generate novel antibiotic structures from either chemical fragments or de novo, starting ...

Receptor-interacting protein kinase 1 (RIPK1) plays a pivotal role in ischemic stroke pathology by mediating necroptosis and promoting neuroinflammation, both of which contribute to secondary brain ...

Quoted technology commercialization company Puretech Health plc is scouting for third parties to fund phase III development ...

Stimvia s.r.o.’s Uris system, which delivers peroneal electrical transcutaneous neuromodulation, successfully treated the symptoms of Parkinson’s disease. The non-invasive device, originally developed ...

The U.S. FDA released another series of regulations for de novo devices, but the attendant regulation is not always available for these de novo devices.

The Medicare Payment Advisory Commission said in a recent report that Medicare spending in the U.S. is poised to nearly double to $1.9 trillion over the coming eight years, a figure that is likely to ...

Trethera Corp. has been awarded a $3 million Small Business Innovation Research (SBIR) grant from the National Institute of Health (NIH) to support evaluation of Trethera’s lead candidate, TRE-515, ...

Dysregulation of the polycomb repressive complex 2 (PRC2) is associated with epigenetic silencing of tumor suppressor genes, leading to alterations in cell proliferation, differentiation and survival ...

Overexpression of focal adhesion kinase (FAK) is linked to worse prognosis and greater risk of metastasis in colorectal, cervical, breast and skin cancers. Despite its attractiveness as a therapeutic ...